[Asia Economy Reporter Lee Seon-ae] Caregen announced on the 26th that it has received approval from the Israel Ministry of Health (MoH) for the Phase 1 clinical trial plan of the intranasal antiviral drug for COVID-19 treatment, 'CG-SpikeDown'.



This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing